Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER_GOV × Immunotherapy × tislelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 4 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 SCLC, Extensive Stage 1 Nasopharyngeal Carcinoma 1 Mid-low Rectal Cancer 1 Melanoma 1 Locally Advanced Rectal Cancer 1 Laryngeal Neoplasms 1 Immunotherapy 1 Hypopharyngeal Neoplasms 1 Colonic Neoplasms 1 Advanced Non-small-cell Lung Cancer 1

Interventions

tislelizumab 1 Oxaliplatin 1 Capecitabine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05479240 2023-06-18

Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer

Fujian Cancer Hospital

Phase 2 Not yet recruiting

Immunotherapy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡